Lorena Losi
Lorena Losi
affiliation: Università di Modena-Reggio Emilia
research area(s): Molecular Biology, Genetics And Genomics
Course: Molecular and Regenerative Medicine
University/Istitution: Università di Modena-Reggio Emilia
1985: graduation in Medicine, University of Modena and Reggio Emila with full marks
1991: PhD in Human Pathology
1993: Specialization in Pathologic Anatomy
Since 1992 researcher at the Institute of Pathology performing research, hospital assistance (histological diagnosis in different pathologies, frozen section diagnosis and autopsies) and teaching in several courses (Medicine, Biology and Medical Biotecnologies).
Member of the Medical Faculty, since november 2005 member of the Faculty of Biosciences and Biotecnologies.

Research experiences:
1990-91 (18 months): Molecular Laboratory at University Institute of Pathology of Lausanne (Switzerland),following years for monthly periods, for two consecutively years (2003-2005)and still today.
Since 2007 collaboration with the Department of Biomedical Sciences: biomolecular mechanisms of 5-ASA (masalazine) in the chemoprevention of colorectal carcinoma.

Technical skills and competences: immunohistochemistry, histochemistry, flow
cytometry, FISH and biomolecular techniques (PCR, sequencing,SSCP),histological
diagnosis of the neoplastic and non neoplastic diseases, mainly of the gastrointestinal tumours.
Research area 1:Pathological diagnosis of gastrointestinal tumours particularly morphological study of precancerous lesions; research of genetic alterations in the neoplastic progression and in the development of sporadic, hereditary and early-onset (< 40 years) colorectal cancers; research of prognostic markers; study of genetic intratumoral heterogeneity and of different mechanisms of neoplastic metastatization in colorectal cancer using immunohistochemical and biomolecular methods.
Since 2007 collaboration with the Department of Biomedical Sciences: biomolecular mechanisms of 5-ASA (masalazine) in the chemoprevention of colorectal carcinoma
Research area 2: role of neoplastic lesions (melanocytic and non) in hereditary cancer syndromes and the importance of immunohistochemical and biomolecular analysis for their identification.
Research area 3: immunophenotypical and biomolecular characterization of ovarian tumours

1. Assessment of K-ras, Smad4 and p53 gene alterations in colorectal metastases and their role in the metastatic process.
Losi L, Luppi G, Benhattar J. Oncol Rep 2004;12:1221-1225.

2. Identification of Muir-Torre Syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability and immunohistochemistry.
Ponti G, Losi L, Di Gregorio C, Roncucci L, Pedroni M, Scarselli A, Benatti P, Seidenari S, Pellacani G, Lembo L, Rossi G, Marino M, Lucci-Cordisco E, Ponz de Leon M. Cancer 2005; 103:1018-1025.

3. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression.
Losi L, Baisse B, Bouzourene H, Benhattar J. Carcinogenesis 2005; 26:916-922.

4. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes.
Losi L, Di Gregorio C, Pedroni M, Ponti G, Roncucci L, Scarselli A, Genuardi M, Baglioni S, Marino M, Rossi G, Benatti P, Maffei S, Menigatti M, Roncari B, Ponz de Leon M. Am J Gastroenterol 2005; 100:2280-2287.

5. Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy.
Losi L, Luppi G, Gavioli M, Iachetta F, Bertolini F, D'Amico R, Jovic G, Bertoni F, Falchi AM, Conte PF. Int J Colorectal Dis 2006; 21:645-651.

6. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre Sindrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G, Losi L, Pedroni M, Lucci-Cordisco E, Di Gregorio C, Pellacani G, Seidenari S. J Invest Dermatol 2006; 126: 2302-2307.

7. Prognostic significance of histological features and biological parameters in stage I (pT1 and pT2) colorectal adenocarcinoma.
Losi L, Ponti G, Di Gregorio C, Marino M, Rossi G, Pedroni M, Benatti P, Roncucci L, Ponz de Leon M. Path Res Pract 2006; 202:663-670.

8. Loss of Smad4 expression predicts liver metastasis in human colorectal cancer.
Losi L, Bouzourene H, Benhattar J. Oncol Rep 2007; 17: 1095-99.

9. Preoperative therapy for lower rectal cancer and modifications in distance from anal sphincter.
Gavioli M, Losi L, Luppi G, Iachetta F, Zironi S, Bertolini F, Falchi AM, Bertoni F, Natalini G. Int J Radiat Oncol Biol Phys, 2007; 69: 370-75.

10. Wnt pathway, angiogenetic and hormonal markers in Sporadic and Familial Adenomatous Polyposis associated Juvenile Nasopharyngeal Angiofibromas (JNA). Ponti G, Losi L, Pellacani G, Rossi GB, Presutti L, Mattioli F, Villari D, Wannesson L, Alicandri Ciufelli M, Izzo P, De Rosa M, Marone P, Seidenari S.
Appl Immunohistochem Mol Morphol 2008; 16: 173-8.

11. Malignant melanoma in patients with hereditary nonpolyposis colorectal cancer Ponti G, Losi L, Pellacani G, Wannesson L, Cesinaro AM, Venesio T, Petti C, Seidenari S. Br J Dermatol 2008; 159:162-8.

12. Bouzourene H, Hutter P, Losi L, Martin P, Benhattar J. Selection of patients with germline MLH1 mutated Lynch syndrome by determination of MLH1 methylation and BRAF mutation. Fam Cancer 2010; 9:167-72.

13. Down-regulation of μ-protocadherin expression is a common event in colorectal carcinogenesis.
Losi L, Parenti S, Ferrarini F, Rivasi F, Gavioli M, Natalini G, Ferrari S, Grande A.
Hum Pathol. 2011; 42:960-71.
No projects are available to students for the current accademic year.